Claim check · Regulatory status, Product identity, Study interpretation
Evidence for an approved medicine and other products with the same peptide name
Claim (representative wording, not a quotation): Studies of an approved semaglutide medicine apply automatically to any product called semaglutide.
Plain-English answer
The trials behind an approved medicine tested that medicine. Their results carry over to another product only when a regulator has found the two equivalent, which is how an FDA-approved generic is judged against a named reference product. FDA states that compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before they are marketed, so such a product does not inherit the trial evidence through its name.
Verdict: Overstated. Part of the claim is supported, but the claim says more than the sources show: a wider population, a stronger outcome, a human result from animal work, or a certainty the design cannot give.
Scope
- Population or organism
- US-regulated injectable semaglutide (Wegovy) and liraglutide (Victoza as the reference product for an approved generic)
- Study design
- Comparison of an FDA-approved product label, FDA statements on compounded drugs, FDA requirements for generic drugs and an FDA approval record
- Boundary
- United States only, on the dates checked. It concerns whether trial evidence transfers, not the content, quality or safety of any specific product, which WPF did not test. It is not advice about any product, and regulatory status is not scientific evidence. Online "research" products are covered by the check on research-use-only labelling.
Strongest evidence
WEGOVY (semaglutide) injection label, Novo Nordisk, DailyMed set ID ee06186f-2aa3-4990-a760-757579d8f77b, version 19, published 2026-06-30 (label revised 06/2026) (Regulatory document)
Population or organism: Adults with obesity or overweight and established cardiovascular disease (Study 1)
Design: FDA-approved prescribing information, Clinical Studies section
Where in the source: Section 14.1: "Study 1 (NCT03574597) was a multi-national, multi-center, placebo-controlled, double-blind trial to determine the effect of WEGOVY injection relative to placebo on major adverse CV events".
FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of 10/01/2026) (Regulatory document)
Population or organism: Compounded GLP-1 drugs, including compounded semaglutide
Design: FDA statement
Where in the source: Section "Concerns with compounded versions of these drugs": "compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed." Section "Salt forms should not be used to compound semaglutide": "some semaglutide products sold by compounders may be the salt forms."
FDA, FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products (content current as of 07/26/2024) (Regulatory document)
Population or organism: Compounded semaglutide products
Design: FDA alert
Where in the source: Paragraph beginning "FDA had also received reports that in some cases, compounders may be using salt forms of semaglutide": "The salt forms are different active ingredients than is used in the approved drugs, which contain the base form of semaglutide."
FDA, Generic Drugs: Questions & Answers (content current as of 09/18/2026) (Regulatory document)
Population or organism: FDA-approved generic drugs in general
Design: FDA explanatory page
Where in the source: "ANDAs must show, among other things, the generic drug is pharmaceutically equivalent and bioequivalent to the brand name drug it references"; "Generic drug companies do not need to repeat the costly clinical trials that establish a drug's safety and effectiveness. Instead, the generic drug manufacturer assures safety and effectiveness by demonstrating that their product is therapeutically equivalent to the brand drug."
FDA Approves First Generic of Once-Daily GLP-1 Injection to Lower Blood Sugar in Patients with Type 2 Diabetes (2024-12-23) and Drugs@FDA record ANDA215503 (Regulatory document)
Population or organism: Generic liraglutide injection referencing Victoza
Design: FDA approval announcement; Drugs@FDA record read through the openFDA API
Where in the source: Announcement: "the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter", approval granted to Hikma Pharmaceuticals USA Inc. openFDA drugsfda record ANDA215503: sponsor HIKMA, liraglutide solution for subcutaneous use, original action 2024-12-23, marketing status Prescription.
Regulatory decision
- Product
- Liraglutide injection (generic), ANDA215503, referencing Victoza
- Indication
- To lower blood sugar in patients with type 2 diabetes (as stated in the announcement title)
- Jurisdiction
- United States (FDA)
- Decision type
- Approval of a generic drug (abbreviated new drug application)
- Decision date
- 2024-12-23
- Official source
- FDA announcement of the first generic referencing Victoza
Regulatory action is context, not scientific evidence about whether a product works.
What remains uncertain
- These are regulator statements about status and process, not measurements of what any particular product contains or how it behaves.
- FDA's wording on salt forms is conditional ("may be"). WPF did not verify how many products are salt forms.
- FDA's statements describe compounded drugs as a category. They do not say any specific compounded product is unsafe or ineffective, and this check does not either.
- The generic-drug page is general and not specific to liraglutide, and the approval announcement does not itself state the equivalence standard.
- Other regulators' rules were not checked and can differ.
What would change the answer
- Bioequivalence or clinical data for a specific non-approved product, which would speak to that product only.
- An FDA approval of a product as a generic of a named reference product, which by FDA's description lets the reference product's evidence stand for it.
- A change in FDA's published position on compounded products.
Exact gaps
- The label was read on DailyMed (National Library of Medicine, which publishes FDA-submitted labels), not on Drugs@FDA.
- Only one approved-generic example (liraglutide) was read in detail; WPF did not search for approved generics of other peptide medicines.
- Products sold online as "research" peptides are not addressed here; see the research-use-only check.
Date checked and review status
Checked: · version 1.6.0
Review status: AI-assisted source verification. Human review: none recorded. Human review is pending and has not happened.
Related pages
Profiles: /directory/semaglutide
Research journeys: /research/journey/semaglutide
What changed?: /research/changes#regulatory_decision
Cite this check
The citation names the version and an address that keeps returning what was checked, even after a newer version is published.
Evidence for an approved medicine and other products with the same peptide name: The trials behind an approved medicine tested that medicine. Their results carry over to another product only when a regulator has found the two equivalent, which is how an FDA-approved generic is judged against a named reference product. FDA states that compounded drugs are not FDA approved and are not reviewed for safety, effectiveness or quality before they are marketed, so such a product does not inherit the trial evidence through its name. Verdict: Overstated. Cited from World Peptide Foundation, Peptide Claims & Evidence, version 1.6.0, claim approved-medicine-evidence-same-peptide-name, checked 2026-11-14. AI-assisted source verification; human review none recorded.
Page:
https://www.worldpeptidefoundation.org/research/check/approved-medicine-evidence-same-peptide-name
Versioned record:
https://www.worldpeptidefoundation.org/api/research/claims/approved-medicine-evidence-same-peptide-name?version=1.6.0
Versioned record: /api/research/claims/approved-medicine-evidence-same-peptide-name?version=1.6.0